Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10817598 | Clinical Biochemistry | 2014 | 22 Pages |
Abstract
Our results demonstrated the clinical validity of the ARCHITECT Gal-3 automated immunoassay for the risk stratification of HF patients. The automation of Gal-3 testing was also cost-effective and might help to preserve hospital budget.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
D. Gruson, M. Mancini, S.A. Ahn, M.F. Rousseau,